Affiliation:
1. V.A. Nasonova Research Institute of Rheumatology
2. V.A. Nasonova Research Institute of Rheumatology; A. S. Loginov Moscow Clinical Scientific Center
Abstract
This article presents the results of international studies of abatacept efficacy and safety and searching for possible predictors of a good response to the therapy with this drug in real clinical practice.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference58 articles.
1. Schiff M. M., Bessette L. Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clinical Rheumatology, 29, 583–591. DOI: 10.1007/s10067–009–1363–0.
2. Aleksandrova EL, Novikiov AA, Nasonov EL. Rol T-kletok v patogeneze revmatoidnogo artrita. [Role of T-cells in pathogenesis of rheumatoid arthritis] Rheum science and practice 2010; 4; 2: 3–9.
3. Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 2007 Sep-Oct; 25 (5 Suppl 46): S 4–11.
4. Korhonen R, Moilanen E. Abatacept, a novel CD 80 / 86-CD 28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009 Apr; 104 (4): 276–84. DOI: 10.1111/j.1742–7843.2009.00375.x.
5. Kremer JM, Genant HK, Moreland LW et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial. Ann Intern Med. 2006; 144: 865–876. DOI: 10.7326/0003–4819–144–12–200606200–00003.